Praxis Precision Medicines, Inc. Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Praxis Precision Medicines, Inc. announced that the European Medical Agency has awarded its Priority Medicines designation for elsunersen for the treatment of SCN2A Gain of Function developmental...

Related Keywords

,Praxis Precision Medicines Inc ,European Medical Agency ,Praxis Precision Medicines ,Priority Medicines ,Markets ,